How can IGXT's Market Cap only be $27M?? -- That should be the first and only question anyone has about this company
at this point in time. Don't ask "Why" - you will find no answer in that. Everything is going great for the company and always has been and there is nothing wrong, it's all only good. Only ask "How can that be?" And then answer your own question which will eventually be: It can't. It can't be. Something is wrong with the price. Something is wrong with the price because that is the only thing left that it could be. And then at that point of realization you should be buying with both hands.
I'm frustrated that people are not "getting it" when it comes to this stock. There are people on this board that will argue and create negativity on topics that are nothing compared to the real thing they should be talking about which is how the market cap of the company could be this low. This is a biotech company and how biotech companies are valued is a straightforward process and this one has never and still isn't getting it's "due" or anything even close to it. But the company just spelled out what is transpiring now and for the rest of 2013 and people need to start understanding what this will mean to the market cap soon because this cannot be ignored for much longer. It just can't. A company with an FDA approved drug who is expecting possibly $10M in 2013 on milestone payments for multiple drugs, sales revenue, royalties, possible $3M upfront non-returnable exclusive rights payment that looks like it is more than possible from what the CEO said, all these things total $10M - and this is trading with a $27M market cap. That just cannot be for much longer. Something will give.
doodie, maybe all your posts are scareing potential investors away. You keep posting the same things over and over. Post the information on other boards to drum up interest in this stock. I agree there are a ton of reasons to hold this abd some of those reasons will come to pass in a very short time and then the pps will move much higher. It might happen over night, but it wasn't last night and may not be tonight, but some morning doodie you will wake up to some very good news, very soon.
so as not to confuse, when I said "expecting possibly $10M in 2013 on milestone payments for multiple drugs, sales revenue, royalties, possible $3M upfront non-returnable exclusive rights payment that looks like it is more than possible from what the CEO said, all these things total $10M - and this is trading with a $27M market cap. "
$10M = $3M possible exclusive payment on ED drug CEO mentioned at Roth + $5M total expected revenue from upfront payments and royalties and revenues from both FDA approved Forfivo drug and not yet approved drugs in 2013 according to companies own projections including upfront payment for filing Rizatriptan film NDA and also the $1M from fully Bioequivalent film partnering coming + $2M cash that is already in the bank.
The market will recognize the value once those revenues start to materialize. that is the way with many companies. this is not a straight forward r&d company, as it does not do new drugs. just new delivery methods.
people need to see the value exposed before they bite into it. give it time.
you are almost there, just give it some more time.
good luck to the company and to us.